171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer
Titel:
171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer
Auteur:
Marmé, F. Wildiers, H. Dirix, L. Armstrong, A. De Cuypere, E. Dalenc, F. Pia Schröder, C. Vuylsteke, P. Brain, E. Kuemmel, S. Pápai, Z. Mueller, C. Brignone, C. Triebel, F.